DE69532817T2 - Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose - Google Patents

Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose Download PDF

Info

Publication number: DE69532817T2
Authority: DE; Germany
Prior art keywords: lower alkyl; use according; hydrocarbyl; membered heterocyclic; heterocyclic aromatic
Prior art date: 1994-11-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE1995632817

Other languages

German (de)

English (en)

Other versions

DE69532817D1 (de

Inventor

Neill A. Giese

Nathalie Lokker

Alan M. Laibelman

Robert M. Scarborough

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Millennium Pharmaceuticals Inc

Original Assignee

Millennium Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-10

Filing date

1995-11-09

Publication date

2005-01-13

1995-11-09 Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc

2004-05-06 Application granted granted Critical

2004-05-06 Publication of DE69532817D1 publication Critical patent/DE69532817D1/de

2005-01-13 Publication of DE69532817T2 publication Critical patent/DE69532817T2/de

2015-11-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims description 15
208000037803 restenosis Diseases 0.000 title claims description 12
201000011510 cancer Diseases 0.000 title claims description 10
201000001320 Atherosclerosis Diseases 0.000 title claims description 9
206010018364 Glomerulonephritis Diseases 0.000 title claims description 8
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims abstract description 87
125000000217 alkyl group Chemical group 0.000 claims abstract description 68
125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 39
108091000080 Phosphotransferase Proteins 0.000 claims abstract description 30
102000020233 phosphotransferase Human genes 0.000 claims abstract description 30
125000002373 5 membered heterocyclic group Chemical group 0.000 claims abstract description 25
125000004070 6 membered heterocyclic group Chemical group 0.000 claims abstract description 25
238000000034 method Methods 0.000 claims abstract description 24
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 22
239000000203 mixture Substances 0.000 claims abstract description 18
125000003118 aryl group Chemical group 0.000 claims abstract description 16
229910052736 halogen Inorganic materials 0.000 claims abstract description 14
150000002367 halogens Chemical class 0.000 claims abstract description 14
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 11
230000002401 inhibitory effect Effects 0.000 claims abstract description 7
230000000694 effects Effects 0.000 claims description 50
102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 32
108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 32
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 22
108091008606 PDGF receptors Proteins 0.000 claims description 21
125000001424 substituent group Chemical group 0.000 claims description 17
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 16
239000000758 substrate Substances 0.000 claims description 14
125000003545 alkoxy group Chemical group 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 6
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
125000003282 alkyl amino group Chemical group 0.000 claims description 3
210000001124 body fluid Anatomy 0.000 claims description 3
239000010839 body fluid Substances 0.000 claims description 3
125000004663 dialkyl amino group Chemical group 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
230000007935 neutral effect Effects 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
125000002877 alkyl aryl group Chemical group 0.000 claims 1
125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
238000002405 diagnostic procedure Methods 0.000 claims 1
238000011477 surgical intervention Methods 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
125000001072 heteroaryl group Chemical group 0.000 abstract description 6
210000004027 cell Anatomy 0.000 description 46
229940125904 compound 1 Drugs 0.000 description 29
102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 25
239000003112 inhibitor Substances 0.000 description 23
102000005962 receptors Human genes 0.000 description 23
108020003175 receptors Proteins 0.000 description 23
230000035578 autophosphorylation Effects 0.000 description 18
-1 hydrocarboyl Chemical group 0.000 description 18
239000000243 solution Substances 0.000 description 17
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 15
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 15
CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 14
230000004663 cell proliferation Effects 0.000 description 13
239000003102 growth factor Substances 0.000 description 13
150000003839 salts Chemical class 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
102000001253 Protein Kinase Human genes 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
108060006633 protein kinase Proteins 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
KOZFSFOOLUUIGY-SOLYNIJKSA-N K-252a Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@](C(=O)OC)(O)[C@]4(C)O1 KOZFSFOOLUUIGY-SOLYNIJKSA-N 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
150000003217 pyrazoles Chemical class 0.000 description 11
201000010099 disease Diseases 0.000 description 10
JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 9
102000001301 EGF receptor Human genes 0.000 description 9
108060006698 EGF receptor Proteins 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
238000011534 incubation Methods 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
239000002253 acid Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000026731 phosphorylation Effects 0.000 description 7
238000006366 phosphorylation reaction Methods 0.000 description 7
230000008569 process Effects 0.000 description 7
239000005483 tyrosine kinase inhibitor Substances 0.000 description 7
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
102000009465 Growth Factor Receptors Human genes 0.000 description 6
108010009202 Growth Factor Receptors Proteins 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
229940043355 kinase inhibitor Drugs 0.000 description 6
239000007788 liquid Substances 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
238000012360 testing method Methods 0.000 description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 5
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 5
108050007372 Fibroblast Growth Factor Proteins 0.000 description 5
102000018233 Fibroblast Growth Factor Human genes 0.000 description 5
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
229920001213 Polysorbate 20 Polymers 0.000 description 5
108090000315 Protein Kinase C Proteins 0.000 description 5
102000003923 Protein Kinase C Human genes 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
239000002585 base Substances 0.000 description 5
239000002775 capsule Substances 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
239000013592 cell lysate Substances 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
230000002255 enzymatic effect Effects 0.000 description 5
229940126864 fibroblast growth factor Drugs 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000003757 phosphotransferase inhibitor Substances 0.000 description 5
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
239000000843 powder Substances 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
102000009076 src-Family Kinases Human genes 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
102000009024 Epidermal Growth Factor Human genes 0.000 description 4
101800003838 Epidermal growth factor Proteins 0.000 description 4
108091008794 FGF receptors Proteins 0.000 description 4
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 4
241000282412 Homo Species 0.000 description 4
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
239000004473 Threonine Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
231100000433 cytotoxic Toxicity 0.000 description 4
230000001472 cytotoxic effect Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
229940116977 epidermal growth factor Drugs 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
239000002609 medium Substances 0.000 description 4
MZGWFOJGTTVLQX-UHFFFAOYSA-N n-(5-phenyl-1h-pyrazol-3-yl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=NN1)C=C1C1=CC=CC=C1 MZGWFOJGTTVLQX-UHFFFAOYSA-N 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000000047 product Substances 0.000 description 4
125000003226 pyrazolyl group Chemical group 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
108010087686 src-Family Kinases Proteins 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 3
102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 3
238000002399 angioplasty Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000004068 intracellular signaling Effects 0.000 description 3
239000006166 lysate Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
230000035407 negative regulation of cell proliferation Effects 0.000 description 3
231100000590 oncogenic Toxicity 0.000 description 3
230000002246 oncogenic effect Effects 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000003909 protein kinase inhibitor Substances 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
108091008598 receptor tyrosine kinases Proteins 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000008054 signal transmission Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
239000003643 water by type Substances 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000283707 Capra Species 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
102100039064 Interleukin-3 Human genes 0.000 description 2
108010002386 Interleukin-3 Proteins 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
239000012979 RPMI medium Substances 0.000 description 2
241000700159 Rattus Species 0.000 description 2
102000001332 SRC Human genes 0.000 description 2
108060006706 SRC Proteins 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000004913 activation Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
235000012538 ammonium bicarbonate Nutrition 0.000 description 2
239000001099 ammonium carbonate Substances 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
235000010290 biphenyl Nutrition 0.000 description 2
239000004305 biphenyl Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000007958 cherry flavor Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002612 dispersion medium Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
125000004446 heteroarylalkyl group Chemical group 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940076264 interleukin-3 Drugs 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
WQQSRRWHOONMOM-UHFFFAOYSA-N n-(2-benzoyl-5-phenylpyrazol-3-yl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 WQQSRRWHOONMOM-UHFFFAOYSA-N 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
108010017843 platelet-derived growth factor A Proteins 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
102000027426 receptor tyrosine kinases Human genes 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
239000003104 tissue culture media Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
238000001262 western blot Methods 0.000 description 2
ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 1
ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 1
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical class OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 1
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
HFCKOMYXGJXBCV-UHFFFAOYSA-N 2-(3-phenylprop-2-enyl)propanedinitrile Chemical compound N#CC(C#N)CC=CC1=CC=CC=C1 HFCKOMYXGJXBCV-UHFFFAOYSA-N 0.000 description 1
WAVNYPVYNSIHNC-UHFFFAOYSA-N 2-benzylidenepropanedinitrile Chemical class N#CC(C#N)=CC1=CC=CC=C1 WAVNYPVYNSIHNC-UHFFFAOYSA-N 0.000 description 1
LIHXMJLRZGFYFT-UHFFFAOYSA-N 2-chloro-n-(5-phenyl-1h-pyrazol-3-yl)benzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=NNC(C=2C=CC=CC=2)=C1 LIHXMJLRZGFYFT-UHFFFAOYSA-N 0.000 description 1
AEEPXYZNJPKDOX-UHFFFAOYSA-N 2-cyano-3-(2,5-dihydroxyphenyl)prop-2-enamide Chemical compound NC(=O)C(C#N)=CC1=CC(O)=CC=C1O AEEPXYZNJPKDOX-UHFFFAOYSA-N 0.000 description 1
LTCUEJCBTQTSHI-UHFFFAOYSA-N 2-fluoro-n-(5-phenyl-1h-pyrazol-3-yl)benzamide Chemical compound FC1=CC=CC=C1C(=O)NC1=NNC(C=2C=CC=CC=2)=C1 LTCUEJCBTQTSHI-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
MCEUEMILDHFTQG-UHFFFAOYSA-N 4-chloro-n-(5-phenyl-1h-pyrazol-3-yl)benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NNC(C=2C=CC=CC=2)=C1 MCEUEMILDHFTQG-UHFFFAOYSA-N 0.000 description 1
PWSZRRFDVPMZGM-UHFFFAOYSA-N 5-phenyl-1h-pyrazol-3-amine Chemical compound N1N=C(N)C=C1C1=CC=CC=C1 PWSZRRFDVPMZGM-UHFFFAOYSA-N 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000699694 Gerbillinae Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
101000827746 Homo sapiens Fibroblast growth factor receptor 1 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000238367 Mya arenaria Species 0.000 description 1
208000034827 Neointima Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 description 1
101710122944 Proto-oncogene tyrosine-protein kinase Src Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
206010038563 Reocclusion Diseases 0.000 description 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000282887 Suidae Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
101710086977 Tyrosine-protein kinase transforming protein Src Proteins 0.000 description 1
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 1
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
125000005037 alkyl phenyl group Chemical group 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000000729 antidote Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000000451 chemical ionisation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
229940126545 compound 53 Drugs 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
150000008049 diazo compounds Chemical class 0.000 description 1
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
229940079919 digestives enzyme preparation Drugs 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229940045109 genistein Drugs 0.000 description 1
235000006539 genistein Nutrition 0.000 description 1
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003966 growth inhibitor Substances 0.000 description 1
125000005059 halophenyl group Chemical group 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000003688 hormone derivative Substances 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
238000003674 kinase activity assay Methods 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000003584 mesangial cell Anatomy 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
229960000907 methylthioninium chloride Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
BPQLHQMJXGFDCM-UHFFFAOYSA-N n-benzyl-5-phenyl-1h-pyrazol-3-amine Chemical compound C=1C=CC=CC=1CNC(=NN1)C=C1C1=CC=CC=C1 BPQLHQMJXGFDCM-UHFFFAOYSA-N 0.000 description 1
125000006606 n-butoxy group Chemical group 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000027405 negative regulation of phosphorylation Effects 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
238000004305 normal phase HPLC Methods 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000001301 oxygen Chemical group 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000035409 positive regulation of cell proliferation Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
235000008476 powdered milk Nutrition 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
229960001285 quercetin Drugs 0.000 description 1
235000005875 quercetin Nutrition 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
102000016914 ras Proteins Human genes 0.000 description 1
108010014186 ras Proteins Proteins 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000009666 routine test Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003333 secondary alcohols Chemical class 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
230000011664 signaling Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
229910052717 sulfur Chemical group 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000009777 vacuum freeze-drying Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
239000009637 wintergreen oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DE1995632817 1994-11-10 1995-11-09 Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose Expired - Lifetime DE69532817T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US33763094A	1994-11-10	1994-11-10
US337630		1994-11-10
PCT/US1995/014723 WO1996014843A2 (fr)	1994-11-10	1995-11-09	Compositions pharmaceutiques a base de pyrazole, agissant comme inhibiteurs des proteines kinases

Publications (2)

Publication Number	Publication Date
DE69532817D1 DE69532817D1 (de)	2004-05-06
DE69532817T2 true DE69532817T2 (de)	2005-01-13

Family

ID=23321325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE1995632817 Expired - Lifetime DE69532817T2 (de)	1994-11-10	1995-11-09	Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose

Country Status (13)

Country	Link
US (1)	US5916908A (fr)
EP (1)	EP0788358B1 (fr)
JP (1)	JPH10509708A (fr)
KR (1)	KR970706813A (fr)
CN (1)	CN1165482A (fr)
AT (1)	ATE262902T1 (fr)
AU (1)	AU700964B2 (fr)
CA (1)	CA2203517A1 (fr)
DE (1)	DE69532817T2 (fr)
ES (1)	ES2219670T3 (fr)
MY (1)	MY113208A (fr)
TW (1)	TW474810B (fr)
WO (1)	WO1996014843A2 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9222253D0 (en) *	1992-10-23	1992-12-09	Celltech Ltd	Chemical compounds
GB9304920D0 (en) *	1993-03-10	1993-04-28	Celltech Ltd	Chemical compounds
GB9304919D0 (en) *	1993-03-10	1993-04-28	Celltech Ltd	Chemical compounds
DE69433594T2 (de) *	1993-12-22	2004-08-05	Celltech R&D Ltd., Slough	Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326699D0 (en) *	1993-12-22	1994-03-02	Celltech Ltd	Chemical compounds
US6245774B1 (en)	1994-06-21	2001-06-12	Celltech Therapeutics Limited	Tri-substituted phenyl or pyridine derivatives
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
GB9526245D0 (en) *	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Chemical compounds
GB9526246D0 (en) *	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Chemical compounds
GB9608435D0 (en) *	1996-04-24	1996-06-26	Celltech Therapeutics Ltd	Chemical compounds
GB9619284D0 (en) *	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
GB9622363D0 (en) *	1996-10-28	1997-01-08	Celltech Therapeutics Ltd	Chemical compounds
WO1998024768A1 (fr) *	1996-12-03	1998-06-11	Banyu Pharmaceutical Co., Ltd.	Nouveaux derives d'uree
GB9625184D0 (en) *	1996-12-04	1997-01-22	Celltech Therapeutics Ltd	Chemical compounds
AU5410498A (en) *	1996-12-12	1998-07-03	Banyu Pharmaceutical Co., Ltd.	Pyrazole derivatives
CA2274593A1 (fr) *	1996-12-13	1998-06-18	Banyu Pharmaceutical Co., Ltd.	Derives d'aminopyrazole
US6180653B1 (en)	1996-12-16	2001-01-30	Banyu Pharmaceutical Co., Ltd.	Aminopyrazole derivatives
US6057329A (en) *	1996-12-23	2000-05-02	Celltech Therapeutics Limited	Fused polycyclic 2-aminopyrimidine derivatives
GB9705361D0 (en) *	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
ATE249217T1 (de)	1997-10-06	2003-09-15	Abbott Gmbh & Co Kg	Indeno(1,2-c)-,naphtho(1,2-c)-und benzo(6, 7)cyclohepta(1,2-c)pyrazolderivate
WO1999017770A1 (fr)	1997-10-06	1999-04-15	Basf Aktiengesellschaft	Derives d'indeno[1,2-c]pyrazole utiles pour inhiber l'activite de tyrosine kinase
US6376527B1 (en)	1998-05-05	2002-04-23	Syntex (U.S.A.) Llc	Pyrazole derivatives-p38 map kinase inhibitors
US6316466B1 (en)	1998-05-05	2001-11-13	Syntex (U.S.A.) Llc	Pyrazole derivatives P-38 MAP kinase inhibitors
HN2000000051A (es) *	1999-05-19	2001-02-02	Pfizer Prod Inc	Derivados heterociclicos utiles como agentes anticancerosos
UA71971C2 (en)	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
TWI262914B (en)	1999-07-02	2006-10-01	Agouron Pharma	Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en)	1999-07-02	2006-11-28	Agouron Pharmaceuticals, Inc.	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PE20010306A1 (es) *	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6387900B1 (en)	1999-08-12	2002-05-14	Pharmacia & Upjohn S.P.A.	3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
AP2002002442A0 (en)	1999-08-12	2002-03-31	Pharmacia Italia Spa	3(5)-Amino-pyrazole derivatives, process for their preparation and their preparation and their use as antitumor agents.
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es)	2000-01-21	2003-12-11	Inc Agouron Pharmaceuticals	Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE60106409T2 (de) *	2000-02-07	2006-02-02	Bristol-Myers Squibb Co.	3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
WO2001079198A1 (fr) *	2000-04-18	2001-10-25	Agouron Pharmaceuticals, Inc.	Pyrazoles permettant d'inhiber des proteines kinases
MXPA03001189A (es)	2000-08-09	2004-05-14	Agouron Pharma	Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas.
ES2238463T3 (es)	2000-08-18	2005-09-01	Agouron Pharmaceuticals, Inc.	Hidroxiimino-fluorenos heterociclicos y uso para inhibir proteina-quinasas.
EP1317447B1 (fr)	2000-09-15	2006-05-17	Vertex Pharmaceuticals Incorporated	Composes de pyrazole pouvant etre utilises comme inhibiteurs de la proteine kinase
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) *	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
CA2432303C (fr)	2000-12-21	2010-04-13	Vertex Pharmaceuticals Incorporated	Composes de pyrazole utilises comme inhibiteurs de la proteine kinase
MEP13408A (en)	2001-05-29	2010-06-10	Bayer Schering Pharma Ag	Cdk inhibiting pyrimidines, production thereof and their use as medicaments
HN2002000156A (es)	2001-07-06	2003-11-27	Inc Agouron Pharmaceuticals	Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
CA2465247C (fr) *	2001-10-26	2010-05-18	Aventis Pharmaceuticals Inc.	Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases
SG159380A1 (en) *	2002-02-06	2010-03-30	Vertex Pharma	Heteroaryl compounds useful as inhibitors of gsk-3
ATE468336T1 (de) *	2002-03-15	2010-06-15	Vertex Pharma	Azolylaminoazine als proteinkinasehemmer
UA77303C2 (en)	2002-06-14	2006-11-15	Pfizer	Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
MY141867A (en) *	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
PT1532145E (pt)	2002-08-02	2007-01-31	Vertex Pharma	Composiçoes de pirazole úteis como inibidores de gsk-3
AR042067A1 (es) *	2002-11-27	2005-06-08	Bayer Pharmaceuticals Corp	Derivados de anilinopirazol utiles en el tratamiento de la diabetes
BR0317548A (pt)	2002-12-19	2005-11-22	Pfizer	Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
US7601718B2 (en) *	2003-02-06	2009-10-13	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
EP1620088A4 (fr) *	2003-04-28	2007-08-29	Bayer Pharmaceuticals Corp	Derives d'acide indole acetique et leur utilisation en tant qu'agents pharmaceutiques
US20070161633A1 (en) *	2003-05-02	2007-07-12	Elan Pharmaceuticals, Inc.	4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
ATE410161T1 (de)	2003-05-02	2008-10-15	Elan Pharm Inc	4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
US20050032868A1 (en) *	2003-05-02	2005-02-10	Garofalo Albert W.	Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
EP1651612B9 (fr)	2003-07-22	2012-09-05	Astex Therapeutics Limited	Composes 1h-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (cdk) et modulateurs de la glycogene synthase kinase-3 (gsk-3)
BRPI0412820A (pt) *	2003-07-25	2006-09-26	Pfizer	compostos de aminopirazol e utilização como inibidores de chk1
ES2314444T3 (es)	2003-08-29	2009-03-16	Pfizer Inc.	Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
JP2007506741A (ja) *	2003-09-23	2007-03-22	メルク　エンド　カムパニー　インコーポレーテッド	向代謝性グルタミン酸受容体のピラゾール系調節剤
CN1902193B (zh) *	2003-12-04	2011-07-13	沃泰克斯药物股份有限公司	可用作蛋白激酶抑制剂的喹喔啉
ATE388149T1 (de)	2004-10-14	2008-03-15	Hoffmann La Roche	Neue azaindol-thiazolinone als krebsmittel
EP1812424A4 (fr) *	2004-11-17	2009-07-08	Miikana Therapeutics Inc	Inhibiteurs de kinase
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US7304074B2 (en)	2005-04-05	2007-12-04	Hoffmann-La Roche Inc.	Substituted 1,5-naphthyridine azolinones
JP2009504771A (ja) *	2005-08-18	2009-02-05	バーテックスファーマシューティカルズインコーポレイテッド	ピラジンキナーゼ阻害剤
WO2007041358A2 (fr) *	2005-09-30	2007-04-12	Miikana Therapeutics, Inc.	Composes pyrazole substitues
MX2008005717A (es) *	2005-11-03	2008-10-15	Vertex Pharma	Aminopirimidinas utiles como inhibidores de la cinasa.
WO2008057940A1 (fr) *	2006-11-02	2008-05-15	Vertex Pharmaceuticals Incorporated	Aminopyridines et aminopyrimidines utiles en tant qu'inhibiteurs de protéines kinases
KR101450356B1 (ko) *	2006-11-24	2014-10-15	에이씨 이뮨 에스.에이.	알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
ES2347721T3 (es) *	2006-12-19	2010-11-03	Vertex Pharmaceuticals, Inc.	Aminopirimidinas utiles como inhibidores de proteina quinasas.
US7737149B2 (en)	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008112642A1 (fr) *	2007-03-09	2008-09-18	Vertex Pharmaceuticals Incorporated	Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
CA2679701A1 (fr) *	2007-03-09	2008-09-18	Vertex Pharmaceuticals Incorporated	Utilisation des aminopyridines comme inhibiteurs de proteines kinases
RU2009137390A (ru) *	2007-03-09	2011-04-20	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Аминопиримидины, пригодные в качестве ингибиторов протеинкиназ
CA2683785A1 (fr)	2007-04-13	2008-10-23	Vertex Pharmaceuticals Incorporated	Aminopyrimidines utilisees en tant qu'inhibiteurs de kinases
JP5389785B2 (ja) *	2007-05-02	2014-01-15	バーテックスファーマシューティカルズインコーポレイテッド	キナーゼ阻害剤として有用なチアゾールおよびピラゾール
AU2008247595A1 (en) *	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
CA2694381A1 (fr) *	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Aminopyrimidines servant d'inhibiteurs de kinases
CA2687966A1 (fr) *	2007-05-24	2008-12-04	Vertex Pharmaceuticals Incorporated	Thiazoles et pyrazoles utiles en tant qu'inhibiteurs de kinase
US20090029992A1 (en) *	2007-06-11	2009-01-29	Agoston Gregory E	Substituted pyrazole compounds
CA2694499A1 (fr)	2007-07-31	2009-02-05	Vertex Pharmaceuticals Incorporated	Procede de preparation de la 5-fluoro-1h-pyrazolo[3,4-b]pyridin-3-amine et des derives de celle-ci
JP2012501971A (ja)	2008-09-03	2012-01-26	バーテックスファーマシューティカルズインコーポレイテッド	共結晶および共結晶を含む薬学的処方物
WO2010129681A1 (fr) *	2009-05-05	2010-11-11	Van Andel Research Institute	Méthodes de traitement de troubles liés à l'autophagie
EP2311823A1 (fr)	2009-10-15	2011-04-20	AC Immune S.A.	Composés de 2,6-diaminopyridine appropriés pour le traitement de maladies liées à des protéines amyloïdes ou pour le traitement de maladies oculaires
NZ700332A (en) *	2010-03-30	2017-06-30	Verseon Corp	Multisubstituted aromatic compounds as inhibitors of thrombin
JP6165733B2 (ja)	2011-09-16	2017-07-19	ノバルティスアーゲー	Ｎ−置換ヘテロシクリルカルボキサミド類
US20140179712A1 (en)	2012-12-21	2014-06-26	Astrazeneca Ab	Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
JP6479749B2 (ja)	2013-03-15	2019-03-06	ヴァーセオンコーポレイション	トロンビン阻害剤としてのハロゲノピラゾール
ES2853483T3 (es)	2013-03-15	2021-09-16	Verseon Int Corporation	Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
CN103232394B (zh) *	2013-05-14	2014-09-24	浙江医药高等专科学校	含吡唑类化合物、其制备方法和用途
US10189810B2 (en)	2014-09-17	2019-01-29	Verseon Corporation	Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CA2977993A1 (fr)	2015-02-27	2016-09-01	Verseon Corporation	Composes pyrazole substitues a utiliser en tant qu'inhibiteurs de serine protease
CN112694474B (zh) *	2019-10-23	2022-03-18	四川大学	吲唑类衍生物及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS49100080A (fr) *	1973-02-01	1974-09-20
US4622330A (en) *	1982-12-20	1986-11-11	Merck & Co., Inc.	Antiprotozoal 3-amino or substituted amino pyrazoles
JPH01258695A (ja) *	1988-04-07	1989-10-16	Yamanouchi Pharmaceut Co Ltd	（ピラゾリルアミノ）メチレンビス（ホスホン酸）誘導体及びその医薬
US5196446A (en) *	1990-04-16	1993-03-23	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Certain indole compounds which inhibit EGF receptor tyrosine kinase
SG64322A1 (en) *	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
EP0541486A1 (fr) *	1991-11-07	1993-05-12	Ciba-Geigy Ag	Conjugates polycycliques
WO1994013643A1 (fr) *	1992-12-17	1994-06-23	Pfizer Inc.	Pyrazoles et pyrazolopyrimidines presentant une activite d'antagonistes du facteur de liberation de la cortitrophine
TW336932B (en) *	1992-12-17	1998-07-21	Pfizer	Amino-substituted pyrazoles
PH30300A (en) *	1993-05-07	1997-01-20	Ciba Geigy Ag	Polycyclic compounds and processes for the preparation thereof
US5605820A (en) *	1994-06-23	1997-02-25	Chemgenics Pharmaceuticals, Inc.	Production of strains having biological activities by sexual crosses between vegetatively incompatible strains of Aspergillus nidulans

1995
- 1995-11-09 AT AT95939917T patent/ATE262902T1/de not_active IP Right Cessation
- 1995-11-09 DE DE1995632817 patent/DE69532817T2/de not_active Expired - Lifetime
- 1995-11-09 WO PCT/US1995/014723 patent/WO1996014843A2/fr not_active Ceased
- 1995-11-09 CA CA002203517A patent/CA2203517A1/fr not_active Abandoned
- 1995-11-09 EP EP95939917A patent/EP0788358B1/fr not_active Expired - Lifetime
- 1995-11-09 US US08/556,178 patent/US5916908A/en not_active Expired - Lifetime
- 1995-11-09 AU AU41561/96A patent/AU700964B2/en not_active Ceased
- 1995-11-09 ES ES95939917T patent/ES2219670T3/es not_active Expired - Lifetime
- 1995-11-09 CN CN95196127A patent/CN1165482A/zh active Pending
- 1995-11-09 KR KR1019970703199A patent/KR970706813A/ko not_active Ceased
- 1995-11-09 JP JP8516253A patent/JPH10509708A/ja not_active Ceased
- 1995-11-10 MY MYPI95003420A patent/MY113208A/en unknown
- 1995-11-10 TW TW084111931A patent/TW474810B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1165482A (zh)	1997-11-19
JPH10509708A (ja)	1998-09-22
KR970706813A (ko)	1997-12-01
ES2219670T3 (es)	2004-12-01
MX9703488A (es)	1998-07-31
AU4156196A (en)	1996-06-06
EP0788358B1 (fr)	2004-03-31
CA2203517A1 (fr)	1996-05-23
DE69532817D1 (de)	2004-05-06
WO1996014843A2 (fr)	1996-05-23
TW474810B (en)	2002-02-01
US5916908A (en)	1999-06-29
WO1996014843A3 (fr)	1996-05-23
ATE262902T1 (de)	2004-04-15
MY113208A (en)	2001-12-31
AU700964B2 (en)	1999-01-14
EP0788358A2 (fr)	1997-08-13

Publication	Publication Date	Title
DE69532817T2 (de)	2005-01-13	Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
DE60032601T2 (de)	2007-11-15	Als antikrebsmittel verwendbare heterocyklische derivate
DE69933573T2 (de)	2007-05-03	Chinazolinderivate als medikamente
DE60305193T2 (de)	2007-06-14	Neue 2-amino-4-oxochinazolone als partielle lxr-kernrezeptoragonisten
DE602004007382T2 (de)	2008-04-17	Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
US5883110A (en)	1999-03-16	Pharmaceutical compositions and methods for modulating signal transduction
DE60021423T2 (de)	2006-04-13	4-substituierte 7-aza-indolin-2-one und ihre verwendung als proteinkinaseinhibitoren
DE60013555T2 (de)	2005-09-29	Verwendung von 4-h-1-benzopyran-4-on-derivaten als inhibitoren der proliferation von glatten muskelzellen
DE60129222T2 (de)	2008-03-06	Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
DE60212836T2 (de)	2007-01-25	Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
DE69818083T2 (de)	2004-07-08	INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE
DE60107835T2 (de)	2005-12-22	Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide
DE60037597T2 (de)	2008-12-11	Imidazol- Derivate
DE69734521T2 (de)	2006-07-06	Kombinatorische indolinonbibliotheken und verwandte produkte und verfahren zur behandlung von erkrankungen
DE69912808T2 (de)	2004-09-30	Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
US20080293699A1 (en)	2008-11-27	Inhibitors of thapsigargin-induced cell death
DE60129934T2 (de)	2008-05-08	Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie
DE60006099T2 (de)	2004-07-08	Chinolinderivate als mek enzym-inhibitoren
DE19921567A1 (de)	2000-11-16	Verwendung von Phthalazine-Derivaten
KR102166665B1 (ko)	2020-10-16	벤질리덴구아니딘 유도체들 및 단백질 미스폴딩 질환들의 치료를 위한 치료적 용도
DE60030164T2 (de)	2007-08-30	3-Heteroarylidenyl-2-Indolinon Derivate für die Modulierung der Aktivität einer Proteinkinase und für die Verwendung bei der Chemotherapie von Krebs
DE10123586A1 (de)	2002-11-28	3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
DE102014009011A1 (de)	2014-12-18	Verfahren zum Inhibieren von DYRK1B
DE69533194T2 (de)	2005-08-11	PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
DE60004340T2 (de)	2004-06-09	Substituierte 1,4-dihydroindeno[1,2-c]pyrazole als inhibitoren von tyrosinkinase

Legal Events

Date	Code	Title	Description
2005-04-28	8364	No opposition during term of opposition